Wilms tumor

Wilms tumor, also called nephroblastoma, arises from developing kidney tissue and usually affects young children. A parent may first notice a painless abdominal swelling. Blood in the urine, abdominal pain or high blood pressure can also occur. These findings require assessment but do not by themselves identify the tumor type.

A rapidly enlarging abdomen with severe pain, faintness or breathing difficulty needs urgent evaluation. A childhood kidney mass may instead be a rhabdoid tumor, clear cell sarcoma of the kidney or another diagnosis; adult renal-cell cancer treatment is not the default for a child.

Imaging establishes the renal origin, the condition of the other kidney, regional nodes and extension into the renal vein or vena cava. Chest imaging evaluates lung involvement. Blood pressure, kidney function and urine testing provide a baseline for both treatment and later comparison.

COG usually begins with nephrectomy and lymph-node sampling for a safely resectable unilateral tumor. SIOP usually gives preoperative chemotherapy in a typical presentation, then operates and classifies the treated specimen. Bilateral disease, major surgical risk and atypical presentations can change the sequence.

Biopsy is not a routine preliminary step for every suspected Wilms tumor. Preoperative biopsy can assign local stage III under COG; SIOP distinguishes percutaneous core biopsy from open biopsy. Ask which system applies before a procedure—combining isolated steps from different protocols can alter treatment unnecessarily.

Stages I–III describe progressively different local surgical situations; stage IV denotes distant spread, while stage V means both kidneys are involved at diagnosis. Bilateral disease is not simply a worse version of stage IV: each kidney also needs its own local assessment. COG and SIOP stage definitions must be interpreted in the context of surgery before or after chemotherapy.

Favorable histology and anaplasia are important distinctions. Focal and diffuse anaplasia are not interchangeable. After preoperative chemotherapy, residual blastemal-type disease carries a different meaning from blastemal tissue in an untreated tumor. Expert pathology review should identify the classification used, margins, nodes and treatment response.

Combined loss of heterozygosity at 1p and 16q, gain of chromosome 1q and selected 11p15 findings can add risk information in defined settings. These are tumor-risk markers, not proof of an inherited syndrome and not necessarily targets for a targeted drug. Their practical consequences depend on the treatment protocol.

The phase III COG AREN2231 study uses molecular and clinical factors to refine favorable-histology treatment, including testing broader eligibility for nephrectomy alone in selected stage I groups. That expansion is a research question, not permission to omit chemotherapy for every completely removed tumor. Trial eligibility and the applicable stratum need confirmation by a participating team.

Treatment ranges from surgery with observation in a tightly selected very-low-risk group to combinations of chemotherapy and radiation for higher-risk disease. Surgical completeness is only one factor: age, histology, tumor characteristics, nodes, spill and biology can change the recommendation.

AREN0532 established a nephrectomy-only approach for children younger than two with stage I favorable-histology tumors weighing under 550 g and meeting the study conditions. This avoided initial chemotherapy for most, but some required treatment for relapse. It demonstrates why an evidence-based low-risk pathway includes careful staging and reliable surveillance, not simply fewer medicines.

For favorable-histology Wilms tumor with lung-only metastases, AREN0533 studied treatment adapted to the lung response after initial chemotherapy. Selected complete responders avoided whole-lung radiation, while incomplete responders and specified higher-risk groups received more intensive therapy. This is not a rule that any disappearing lung nodule makes radiation unnecessary.

Subsequent analyses found that 1q gain remained important for outcome, including among some rapid responders. The number and size of nodules alone do not settle the decision. Review the baseline scan, interval response, molecular results and whether all lesions were confidently metastatic.

When both kidneys are involved, preoperative chemotherapy can make nephron-sparing surgery more feasible. The aim is to remove cancer while retaining functioning renal tissue. The two sides may have different histology and surgical options, so planning requires pediatric oncology, experienced renal surgeons, radiology and pathology together.

AREN0534 used defined reassessment points and a limited preoperative treatment period rather than indefinite chemotherapy while waiting for shrinkage. A poorly shrinking mass needs reassessment; it does not automatically justify repeatedly adding chemotherapy. Surgery may still require removal of one kidney, partial resections or another individualized combination.

Long-term AREN0534 follow-up identified later kidney events as well as early relapses. Bilateral or predisposed disease therefore needs a follow-up plan that considers new tumors and remaining kidney function beyond the initial treatment period.

Bilateral or multifocal tumors, a young presentation, overgrowth or body asymmetry, aniridia, genitourinary differences, kidney disease or a family history can prompt genetic evaluation. Relevant conditions include Beckwith–Wiedemann spectrum, WAGR and WT1-related disorders. A negative blood test may not resolve every mosaic or imprinting-related condition.

Surveillance depends on the actual syndrome and regional guidance. The updated AACR recommendations use regular ultrasound for several established predispositions, with age limits and additional tumor screening determined by the condition. Genetic counseling should explain implications for the other kidney, relatives and long-term renal health.

Relapse treatment depends strongly on the original drugs and radiation, relapse location, time course and histology. A child previously treated with two drugs does not face the same decision as one who has already received intensive multiagent therapy. Local surgery or radiation may remain part of a combined salvage plan.

COG AREN1921 studies combination chemotherapy for newly diagnosed diffuse anaplastic Wilms tumor and relapsed favorable-histology disease, with separate risk groups and regimens. It is a protocol-defined research pathway, not one universal relapse recipe. Ask whether a trial is suitable before additional treatment affects eligibility, and confirm current participation directly with the center.

After treatment, follow-up has two jobs: detect recurrence or a new tumor when relevant, and protect long-term health. Blood pressure, urine protein and kidney function deserve attention, especially after bilateral surgery or in a predisposition syndrome. Imaging frequency should follow the child's risk and protocol rather than an indefinite high-intensity scan schedule.

Doxorubicin exposure may require cardiac monitoring; abdominal or chest radiation and certain chemotherapy drugs can affect growth, fertility and later cancer risk. Maintain a treatment summary with cumulative medicines and radiation fields so survivorship care can be tailored. School, activity and emotional recovery also belong in the plan.